Bottneuro AG

Bottneuro AG is at the forefront of medical equipment manufacturing, dedicated to pioneering the future of personalized neurological care. With a strong focus on developing cutting-edge solutions for neurodegenerative diseases, particularly Alzheimer's disease, Bottneuro AG's mission is to improve the quality of life for patients by leveraging advanced technologies to create innovative, non-invasive treatments that are both effective and accessible.

Bottneuro AG has developed the Miamind® Neurostimulator, a groundbreaking, patient-specific device designed for transcranial electrical stimulation (tES). This non-invasive, home-based medical device is tailored to the individual needs of patients. By utilizing 3D-printed, custom-made caps based on MRI scans, Bottneuro AG's device ensures precise stimulation of the brain's cortical regions, enhancing the treatment's effectiveness. Bottneuro AG is committed to quality and safety, reflected in a rigorous approach to regulatory compliance. The Miamind® Neurostimulator is registered with Swissmedic and the British regulatory authority as a custom-made device, paving the way for its use in clinical settings across Europe. Bottneuro AG is actively pursuing FDA and CE marking to expand its reach globally.

Located at Novartis Campus, Lichtstrasse 35, Lichtstrasse 35, 4056, CH, Bottneuro AG invites neurologists, psychiatrists, researchers, and healthcare providers to join in the mission to revolutionize neurological care. Together, it is possible to make a profound difference in the lives of millions of patients and their families. We invite the manager of Bottneuro AG to create a customized and exclusive company showcase and product listing on our platform.